Picture of Indivior logo

INDV Indivior News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

REG - Indivior PLC - JP Morgan Healthcare Conference <Origin Href="QuoteRef">INDV.L</Origin>

RNS Number : 5861T
Indivior PLC
09 January 2017

Indivior PLC (the 'Company')

Shaun Thaxter, CEO of Indivior PLC is presenting at the JP Morgan Healthcare Conference on January 11th, 2017 at 4pm Pacific time (12am UK time). A link to the webcast of the presentation is provided and the slides can be downloaded in pdf format on the Company's website at www.indivior.com. In addition, a playback of the presentation will be available for 3 months.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its robust, global opioid dependence portfolio, Indivior has a strong pipeline of product candidates designed to both expand treatments in opioid dependence and address other chronic diseases of addiction - including alcohol use disorder, cocaine intoxication and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio is available in over 40 countries worldwide. Its name is a fusion of the words individual and endeavor and its logo radiates the company's patient-centered holistic focus on expanding access to high-quality treatment services for addiction worldwide. For additional product information, please visit www.indivior.com

Investor Enquiries

Tom Corran, IR Director, Indivior PLC

+44 1753 423965

tom.corran@indivior.com


This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSSAFMMFWSESF

Recent news on Indivior

See all news